stockrowClimb Bio, Inc. (CLYM) vs Puma Biotechnology, Inc. (PBYI)
- Climb Bio, Inc. CLYM 10.28 +15.90%
- Puma Biotechnology, Inc. PBYI 8.27 −15.35%
Climb Bio, Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. Climb Bio, Inc. and Puma Biotechnology, Inc. are of similar size ($509.5M and $504.3M). Climb Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 15.3×. Puma Biotechnology, Inc. has the higher net margin (11.6% vs 0.00%) and the higher return on invested capital (42.6% vs −71.7%). Across the 12 metrics below, Puma Biotechnology, Inc. leads on 10 and Climb Bio, Inc. on 2.
Valuation
Profitability
| Metric | CLYM | PBYI | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 74.83% | 68.51% |
| Operating margin | 0.00% | 13.16% | 0.00% |
| Net margin | 0.00% | 11.55% | 0.00% |
| Free cash flow margin | 0.00% | 17.79% | 0.00% |
| Return on equity | (27.10%) | 21.97% | (51.96%) |
| Return on assets | (26.27%) | 13.78% | (46.06%) |
| Return on invested capital | (71.73%) | 42.61% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack